controlled with amlodipine 10 mg or valsartan mg alone or with Exforge 5 mg / mg. Exforge . No drug-drug interaction studies have been performed with Exforge and other medicinal products. Read the package leaflet before use. Exforge 5 mg/ mg: 41 Exforge 10 mg/ mg: 42 SH EXF APL JUN15 CL V8 COR FEB17 CL. PATIENT PACKAGE INSERT. EXFORGE is a high blood pressure medication. Learn more about how to * EXFORGE is a CCB/ARB single-pill combination product. It contains 2 prescription.
| Author: | Kikus JoJodal |
| Country: | Montenegro |
| Language: | English (Spanish) |
| Genre: | Love |
| Published (Last): | 8 October 2006 |
| Pages: | 256 |
| PDF File Size: | 11.79 Mb |
| ePub File Size: | 5.21 Mb |
| ISBN: | 632-6-34286-229-4 |
| Downloads: | 33127 |
| Price: | Free* [*Free Regsitration Required] |
| Uploader: | JoJora |
The way to take this medicine: Marketing authorisation holder 8. To email a medicine you must sign up and log in. The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. Please enter your name Please enter your email Your email is invalid. To be taken into account with concomitant use Others In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin. Uncommon Insomnia, mood changes including anxietydepression, tremor, dysgeusia, syncope, hypoesthesia, visual disturbance including diplopiatinnitus, hypotension, dyspnoea, rhinitis, vomiting, dyspepsia, alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, exanthema, myalgia, muscle cramps, pain, micturition disorder, increased urinary frequency, impotence, gynaecomastia, chest pain, malaise, weight increase, weight decrease.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Thrombocytopenia, sometimes with purpura.
Exforge 5mg/80mg film coated tablets
If hypotension occurs with Exforge, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. They can help you balance the risks and the benefits of this medicine during pregnancy. No information is available regarding the use of Exforge during breast-feeding, therefore Exforge is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Store in the original package in order to protect from moisture.
It is Schedule 4: Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome have been reported. Amlodipine has been studied in patients with chronic stable angina, vasospastic angina and angiographically documented coronary artery disease.
Each packkage tablet contains 5 mg of amlodipine as amlodipine besylate and mg of valsartan. Date of revision of the text.
Please check and try again Agree to Terms required. Aortic and mitral valve stenosis As with all other vasodilators, special caution is indicated in patients suffering from mitral stenosis or significant aortic stenosis that is not high grade.
Not a valid value. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started. Active ingredient valsartan amlodipine besilate. MedDRA System organ class. Plasma concentrations correlate with effect in both young and elderly patients.
However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy RR 0. Inhibitors of the uptake transporter rifampicin, ciclosporin or efflux transporter ritonavir The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2.
Interactions linked to valsartan Concomitant use not recommended Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, including valsartan.
The increased plasma levels of angiotensin II following AT 1 receptor blockade pacoage valsartan may stimulate the unblocked receptor subtype AT 2which appears to counterbalance the effect of the AT 1 receptor. The antihypertensive effect persists over 24 hours after administration. Carcinogenesis, mutagenesis Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0. Valsartan does not exhibit any partial agonist activity at the AT 1 receptor and has much about 20,fold greater affinity for the AT 1 receptor than for the AT 2 pzckage.
Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels heparin, etc.
Since there is no exforfe on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to packaage associated with coughing.
EXFORGE & EXFORGE HCT
This is required Error: Kidney transplantation To date there is no experience of the inzert use of Exforge in patients who have had a recent kidney transplantation. Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers.
Exforge HCT is indicated ONLY as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or exflrge dual-component formulation with a single component formulation, all components at the same dose level.
High Blood Pressure Medication | EXFORGE & EXFORGE HCT
Caution should be exercised in patients with liver disease see section 4. The safety of amlodipine in human pregnancy has not been established. In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous packkage.
Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate. In a long-term, placebo-controlled study PRAISE-2 of amlodipine in patients with NYHA New York Heart Association Classification III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.